{
  "docId": "019de077-7395-77e8-a759-85ee5ceb6441",
  "docSlug": "d10c7e5183f0665a04c27575aa737d7a",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 42,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide highlights specific clinical trial names and their associated indications, with a focus on the camizestrant program.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-7395-77e8-a759-85ee5ceb6441/17",
  "deckHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441",
  "deckJsonHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441.json",
  "deckAnchorHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.52,
        "y": 0.23
      },
      "kind": "callout",
      "text": "camizestrant potential best-in-class next generation SERD with differentiated programme in HR+ HER2- breast cancer",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "feb945a0-7a8d-4f57-994e-68309c3855c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.52,
        "y": 0.55
      },
      "kind": "diagram",
      "text": "Matrix of SERENA and CAMBRIA trials across 1L/early and prevalent/incident populations",
      "attrs": null,
      "subkind": "nxn-matrix",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef8ae981-0576-4a4d-88e8-3604a501d76b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "DATROWAY (datopotamab deruxtecan-dlnk): AVANZAR (NSCLC), TROPION-Breast02 (TNBC)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "126238ca-d8a9-4f39-8293-5efea0262548",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "ENHERTU (fam-trastuzumab deruxtecan-nxki): DESTINY-Breast09, 11, 05 (HER2+)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d78be30-aae1-4768-a1e0-81db5c9dbcaf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "IMFINZI (durvalumab): VOLGA (MIBC), POTOMAC (NMIBC), MATTERHORN (GC/GEJ)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4dd1e41-4b82-4aaa-84c6-f3c93e2fff51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.52,
        "y": 0.83
      },
      "kind": "metric",
      "text": "SERENA-6 first camizestrant Phase III readout in H2 2025",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "200597d2-de92-460c-8a12-a4d7b006a907",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "Indication expansion and NME Phase III trials expand ambition in key tumour types",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40bbe44d-84a0-41fd-a434-2616b8e5c356",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology – select Phase III readouts in 2025",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "046e20c5-ef1d-4c5e-b733-ff4a955df63b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "matrix-nxn",
      "slug": null,
      "matchId": "07a15832-5876-4078-93d1-fdcc1b4c7f53",
      "evidence": "The clinical trial landscape is presented as a 2x2 grid mapping trial phases/types against patient populations.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 25,
      "from": 17,
      "beatId": "e47ffa97-7762-483f-b704-045948218cac",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "The slides use visual aids and key messages to help the audience visualize the company's growth momentum and future prospects.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 17,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0642f45f-f82f-4cf0-ac20-36b05c74bfb1",
      "evidence": "The slides use the golden circle framework to explain the company's growth momentum and future prospects.",
      "position": 1,
      "objective": "Why is AstraZeneca's growth sustainable?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}